Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMG 531 Phase 3 in Japanese ITP
NCT00603642Phase 3Completed
- Sponsor
- Amgen
- Start
- Oct 2007
- Primary completion
- Apr 2009
- Modality
- Recombinant Proteins and Enzymes
01
Overview
Phase 3, randomised, double-blind trial in immune thrombocytopenic purpura (ITP) comparing AMG 531 with Placebo (2 arms). Primary endpoint: Weeks With Weekly Platelet Response at 12 weeks. Started Oct 2007; status: completed.
02
Drugs
romiplostim
03
Conditions
immune thrombocytopenic purpura (ITP)
Beyond the preview
Go deeper on NCT00603642.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00603642.